Martin Vander Weyer Martin Vander Weyer

Never mind the banks, look at what pharma giants have been mis-selling

The biggest mis-selling scandal to break this month was not the one which involved banks forcing small business borrowers to buy expensive interest-rate hedging contracts, under threat of not lending to them at all if they refused. The FSA hasn’t got to the bottom of that one yet: in terms of identifiable victims it could be at least as damaging to the reputation of the banks as the Libor scam.

Already a subscriber? Log in

Keep reading with a free trial

Subscribe and get your first month of online and app access for free. After that it’s just £1 a week.

There’s no commitment, you can cancel any time.


Unlock more articles


Martin Vander Weyer
Written by
Martin Vander Weyer
Martin Vander Weyer is business editor of The Spectator. He writes the weekly Any Other Business column.

Topics in this article


Don't miss out

Join the conversation with other Spectator readers. Subscribe to leave a comment.

Already a subscriber? Log in